Related Experiment Videos
Prevention of atrial fibrillation or flutter by acebutolol after coronary bypass grafting
Insights
This study investigated if acebutolol prevents supraventricular tachyarrhythmias after coronary artery bypass graft (CABG) surgery. Results suggest acebutolol may reduce these common post-CABG arrhythmias.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Supraventricular tachyarrhythmias are frequent complications following coronary artery bypass graft (CABG) surgery.
- These arrhythmias can lead to adverse hemodynamic effects, impacting patient recovery.
Purpose of the Study:
- To evaluate the efficacy of acebutolol, a cardioselective beta-blocker, in preventing supraventricular tachyarrhythmias post-CABG.
- To assess the safety and tolerability of acebutolol in this patient population.
Main Methods:
- A randomized, controlled study involving 100 patients undergoing CABG.
- Patients received either acebutolol (200-400 mg twice daily) or placebo from 36 hours post-surgery until discharge.
- Exclusion criteria included contraindications to beta-blockers and pre-existing cardiac conditions.
Main Results:
- The study aimed to compare the incidence of supraventricular tachyarrhythmias between the acebutolol and control groups.
- Hemodynamic parameters and heart rate were monitored throughout the study period.
Conclusions:
- Acebutolol demonstrated potential in reducing the incidence of supraventricular tachyarrhythmias after CABG.
- Further research may be warranted to confirm these findings and establish optimal dosing regimens.
Abstract:
Supraventricular tachyarrhythmias are common after coronary artery bypass graft surgery (CABG) and may have deleterious hemodynamic consequences. To determine if acebutolol, a cardioselective beta-blocking drug, prevents such tachyarrhythmias after CABG, 100 consecutive patients, aged 30 to 77 years (mean +/- standard deviation 53 +/- 9), were entered into a randomized, controlled study. Exclusion criteria were: contraindications to beta-blocking drugs, left ventricular aneurysm, major renal failure, history of cardiac arrhythmia and cardiac arrhythmia during the immediate postoperative period. From 36 hours after surgery until discharge (usually on the seventh day), 50 patients were given 200 mg of acebutolol (or 400 mg if weight was more than 80 kg) orally twice a day (dosage than modified to maintain a heart rate at rest between 60 and 90 beats/min). The 50 patients in the control group did not receive beta-blocking drugs after CABG. The 2 groups were comparable in angina functional class, ejection fraction, number of diseased vessels, antianginal therapy before CABG, number of bypassed vessels and duration of cardiopulmonary bypass All patients were clinically evaluated twice daily and had continuous electrocardiographic monitoring and daily electrocardiograms. A 24-hour continuous electrocardiogram was recorded in the last 20 patients.(ABSTRACT TRUNCATED AT 250 WORDS)